TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.

Christoph D Spinner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.